We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$980M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+25.82%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$183M
AUM Growth
+$11.2M
(+6.5%)
Cap. Flow
+$12.8M
Cap. Flow
% of AUM
7.01%
Top 10 Holdings %
Top 10 Hldgs %
33.05%
Holding
110
New
26
Increased
27
Reduced
30
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
+$9.45M |
| 2 |
Aclaris Therapeutics
ACRS
|
+$6.59M |
| 3 |
MRUS
Merus
MRUS
|
+$5.65M |
| 4 |
RACB
Research Alliance Corp. II Class A Common Stock
RACB
|
+$5.12M |
| 5 |
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
|
+$4.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vericel Corp
VCEL
|
+$7.21M |
| 2 |
EPIX
ESSA Pharma
EPIX
|
+$5.8M |
| 3 |
Delcath Systems
DCTH
|
+$5.74M |
| 4 |
Sutro Biopharma
STRO
|
+$4.02M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$2.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.57% |
| 2 | Financials | 3.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KALV
51
DELISTED
KalVista Pharmaceuticals
KALV
| $1.28M | 0.7% |
+50,000
| New | +$1.31M |
|
|
ETNB
52
DELISTED
89bio
ETNB
| $1.18M | 0.65% |
50,007
+6,000
| +14% | +$138K |
|
53
Cogent Biosciences
COGT
$7.07B
| $1.05M | 0.57% |
120,000
-115,066
| -49% | -$1.11M |
|
54
Cellectar Biosciences
CLRB
$20.2M
| $976K | 0.53% |
2,021
-3,888
| -66% | -$2.31M |
|
|
AKRO
55
DELISTED
Akero Therapeutics
AKRO
| $928K | 0.51% |
32,000
-3,179
| -9% | -$96.2K |
|
56
United Therapeutics
UTHR
$26.2B
| $897K | 0.49% |
5,364
| – | – |
|
|
MRTX
57
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $857K | 0.47% |
5,000
-15,000
| -75% | -$2.97M |
|
58
Immunovant
IMVT
$8.11B
| $808K | 0.44% |
50,400
-49,600
| -50% | -$1.31M |
|
|
ISEE
59
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $804K | 0.44% |
130,043
| – | – |
|
|
SURF
60
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $780K | 0.43% |
100,000
-30,000
| -23% | -$300K |
|
|
SGEN
61
DELISTED
Seagen Inc. Common Stock
SGEN
| $694K | 0.38% |
5,000
-2,509
| -33% | -$404K |
|
62
KALA BIO
KALA
$13.6M
| $689K | 0.38% |
41
| – | – |
|
63
Compugen
CGEN
$220M
| $644K | 0.35% |
75,000
-75,550
| -50% | -$838K |
|
|
TRIL
64
DELISTED
Trillium Therapeutics Inc.
TRIL
| $644K | 0.35% |
60,000
-50,000
| -45% | -$618K |
|
|
OTIC
65
DELISTED
Otonomy, Inc.
OTIC
| $640K | 0.35% |
250,995
-12,956
| -5% | -$53.1K |
|
|
APTO
66
DELISTED
Aptose Biosciences, Inc.
APTO
| $598K | 0.33% |
+222
| New | +$440K |
|
|
MREO
67
Mereo BioPharma
MREO
$50.3M
| $590K | 0.32% |
175,000
-105,000
| -38% | -$371K |
|
|
CYPH
68
Cypherpunk Technologies Inc
CYPH
$66.6M
| $570K | 0.31% |
30,000
+2,500
| +9% | +$59.5K |
|
69
CALL
Wave Life Sciences
WVE
$1.13B
| $561K | 0.31% |
+100,000
| New | +$961K |
|
|
BLRX
70
BioLineRX
BLRX
$11.7M
| $558K | 0.3% |
+5,000
| New | +$601K |
|
71
Travere Therapeutics
TVTX
$5.33B
| $499K | 0.27% |
+20,000
| New | +$553K |
|
|
72
Delcath Systems
DCTH
$416M
| $497K | 0.27% |
40,000
-311,616
| -89% | -$5.74M |
|
73
Immatics
IMTX
$1.26B
| $469K | 0.26% |
+41,797
| New | +$474K |
|
74
Viridian Therapeutics
VRDN
$2.2B
| $461K | 0.25% |
+27,586
| New | +$516K |
|
75
Syndax Pharmaceuticals
SNDX
$1.73B
| $447K | 0.24% |
20,000
-10,000
| -33% | -$226K |
|
Similar funds
BIP
MVM
MFWP
FCM
KL
GFP
ADIC
PCM
Silverarc Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Silverarc Capital Management held 110 positions worth $183M, up 6.5% from $172M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Silverarc Capital Management deployed $12.8M of net new capital in Q1 2021, opening 26 new positions and adding to 27 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 500,000 shares worth $1.71M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Vericel Corp, an estimated $7.21M trimmed.
- Silverarc Capital Management's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 500,000 shares worth $1.71M.
- Silverarc Capital Management added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2021, an estimated $2.72M increase.
- Silverarc Capital Management's biggest Q1 2021 reduction was Vericel Corp, cutting an estimated $7.21M.
- Silverarc Capital Management fully exited Sutro Biopharma in Q1 2021, selling an estimated $4.02M.
- Silverarc Capital Management's ten largest holdings make up 33% of its $183M portfolio in Q1 2021.
- Silverarc Capital Management opened 26 new positions and closed 19 in Q1 2021.
- Silverarc Capital Management's portfolio value rose 6.5% quarter-over-quarter to $183M.
Based on Silverarc Capital Management's 13F filing for Q1 2021, filed 18 May 2021.